Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report)'s stock price gapped up before the market opened on Monday . The stock had previously closed at $11.14, but opened at $11.55. Gyre Therapeutics shares last traded at $12.17, with a volume of 35,423 shares changing hands.
Gyre Therapeutics Trading Up 9.5 %
The business has a 50-day moving average price of $12.86 and a two-hundred day moving average price of $12.61.
Institutional Investors Weigh In On Gyre Therapeutics
A number of large investors have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. lifted its stake in Gyre Therapeutics by 392.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company's stock worth $1,425,000 after purchasing an additional 90,557 shares during the last quarter. Rhumbline Advisers bought a new stake in shares of Gyre Therapeutics during the 2nd quarter worth $123,000. Renaissance Technologies LLC bought a new stake in shares of Gyre Therapeutics during the 2nd quarter worth $166,000. WINTON GROUP Ltd acquired a new stake in Gyre Therapeutics in the second quarter valued at about $220,000. Finally, Bank of New York Mellon Corp bought a new position in Gyre Therapeutics in the second quarter valued at about $218,000. 23.99% of the stock is currently owned by institutional investors and hedge funds.
Gyre Therapeutics Company Profile
(
Get Free Report)
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
See Also
Before you consider Gyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.
While Gyre Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
